News | May 03, 2025
RPG Life Sciences posts Q4 FY25 net profit at Rs. 117.35 Cr
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
The consignment of USFDA qualified Metformin (1000mg) was received by the province of Mendoza for distribution in the public health system
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
EBITDA margins expand to 31.3%
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
Morepen Laboratories approves hiving off of medical devices business
Subscribe To Our Newsletter & Stay Updated
